NIVF revenueFY2025$23.71M
- FY YoY
- +336.3%
NIVF revenue was $23.71M for fiscal 2025 (ended Dec 31, 2025), up 336.3% from fiscal 2024. It rose in 3 of the last 4 fiscal years. Fiscal 2025 is the highest of the 5 fiscal years on file.
NewGenIvf Group Limited (NIVF) financials
For fiscal 2025 (ended Dec 31, 2025), NewGenIvf Group Limited reported $23.71M of revenue and $9.88M of net income.
- Revenue, FY2025
- $23.71M
- Revenue growth, YoY
- +336.3%
- Net income, FY2025
- $9.88M
- Net margin
- 41.7%
- Free cash flow, FY2025
- -$11.06M
- EPS, diluted, FY2025
- $3.04
- Cash
- $758.6K
- Total debt
- $4.10M
- P/E
- 0.46
- P/S
- 0.19
- Market cap
- $4.5M
FY2021FY2025
FY2021FY2025
FY2021FY2025
NIVF revenue and earnings growth
NIVF net incomeFY2025$9.88M
NIVF net income was $9.88M for fiscal 2025 (ended Dec 31, 2025), compared with -$524.6K in fiscal 2024. Fiscal 2025 is the highest of the 5 fiscal years on file.
NIVF EPSFY2025$3.04
NIVF diluted EPS was $3.04 for fiscal 2025 (ended Dec 31, 2025).
NIVF free cash flowFY2025-$11.06M
NIVF free cash flow was -$11.06M for fiscal 2025 (ended Dec 31, 2025), compared with -$8.32M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $23.71M | $5.43M | $5.14M | $5.94M | $4.12M |
| Cost of revenue | $3.77M | $3.61M | $3.45M | $4.41M | $3.09M |
| Gross profit | $955.8K | $1.83M | $1.68M | $1.54M | $1.02M |
| Selling, general and admin | $10.49M | $2.78M | $1.62M | $1.10M | $801.3K |
| Operating income | -$10.73M | -$1.16M | $42.2K | $398.7K | $198.8K |
| Interest expense | - | $765.2K | - | - | - |
| Pre-tax income | $9.73M | -$960.8K | $108.4K | $344.0K | $156.2K |
| Income tax | - | -$486.7K | - | $208.1K | $294.7K |
| Net income | $9.88M | -$524.6K | $130.2K | $458.7K | -$533 |
| EPS, basic | $214.73 | -$4408.76 | $13019.30 | $4.72 | $0.00 |
| EPS, diluted | $3.04 | -$4408.76 | $13019.30 | $4.72 | $0.00 |
| Diluted shares | 3.3M | 119 | 10 | 28,797 | 560,000 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $758.6K | $457.7K | $54.1K | $27.6K | $28.8K |
| Receivables | $166.5K | $49.2K | $9.4K | $13.0K | - |
| Inventory | $335.4K | $80.8K | $126.3K | $46.9K | - |
| Current assets | $7.38M | $3.17M | $2.46M | $2.40M | - |
| Total assets | $32.72M | $3.58M | $4.49M | $2.90M | - |
| Current liabilities | $2.37M | $2.72M | $1.12M | $2.56M | - |
| Long-term debt | $4.10M | $2.33M | - | - | - |
| Total debt | $4.10M | $2.33M | - | - | - |
| Total liabilities | $6.74M | $5.06M | $1.24M | $2.80M | - |
| Shareholders' equity | $26.63M | -$1.05M | $3.25M | $100.7K | -$914.9K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.93M | -$8.26M | -$1.77M | $1.71M | $1.43M |
| Capital expenditures | $135.0K | $53.0K | $69.8K | $94.5K | $16.6K |
| Free cash flow | -$11.06M | -$8.32M | -$1.84M | $1.62M | $1.42M |
| Investing cash flow | -$7.56M | -$53.0K | -$69.8K | -$94.5K | -$16.6K |
| Financing cash flow | $18.99M | $8.68M | $1.88M | -$1.63M | -$1.54M |
| Stock-based compensation | - | - | - | $240.0K | $200.0K |
| Depreciation and amortization | $188.1K | $19.5K | $31.2K | $100.5K | $166.7K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | 336.3% | 5.8% | -13.6% | 44.3% | - |
| Net income growth, YoY | - | - | -71.6% | - | - |
| Gross margin | 4.0% | 33.6% | 32.7% | 25.9% | 24.9% |
| Operating margin | -45.2% | -21.4% | 0.8% | 6.7% | 4.8% |
| Net margin | 41.7% | -9.7% | 2.5% | 7.7% | -0.0% |
| Free cash flow margin | -46.7% | -153.1% | -35.7% | 27.2% | 34.4% |
| Return on equity | 37.1% | - | 4.0% | 455.6% | - |
| Return on assets | 30.2% | -14.7% | 2.9% | 15.8% | - |
| Current ratio | 3.12 | 1.17 | 2.19 | 0.94 | - |
| Debt to equity | 0.15 | - | - | - | - |
Source: XBRL data NewGenIvf Group Limited files with the SEC, latest filing dated Mar 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NIVF peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NIVF | $23.71M | +336.3% | $9.88M | 41.7% | $4.5M |
| FMS | €19.63B | +1.5% | €978.37M | 5.0% | $13.07B |
| DVA | $14.17B | +6.4% | $920.08M | 6.5% | $12.04B |
| SHC | $1.23B | +6.9% | $173.47M | 14.1% | $4.57B |
| PGNY | $1.34B | +5.5% | $91.02M | 6.8% | $2.67B |
| AGL | $6.00B | +2.0% | -$87.10M | -1.5% | $1.90B |
| VMD | $310.37M | +21.8% | $15.89M | 5.1% | $346.0M |
| CCEL | $31.13M | -2.0% | -$1.95M | -6.2% | $39.4M |
NIVF FAQ
9 questionsWhat is NIVF revenue?
NewGenIvf Group Limited (NIVF) reported $23.71M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 336.3% from the year before.Is NIVF profitable?
Yes. NewGenIvf Group Limited earned $9.88M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 41.7%.How much cash and debt does NIVF have?
NewGenIvf Group Limited reported $758.6K in cash and cash equivalents and $4.10M of debt on its most recent balance sheet in SEC filings.How fast is NIVF revenue growing?
NewGenIvf Group Limited's revenue changed +336.3% in fiscal 2025, to $23.71M.What is NIVF gross margin?
NewGenIvf Group Limited's gross profit was $955.8K on $23.71M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 4.0%.What is NIVF free cash flow?
NewGenIvf Group Limited generated -$11.06M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$10.93M less capital expenditures.What is NIVF earnings per share?
Diluted earnings per share were $3.04 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NIVF last report financial results?
The latest statements here come from NewGenIvf Group Limited's 20-F filed on Mar 31, 2026, covering the period ended Dec 31, 2025.Where does this NIVF financial data come from?
Quantisnow builds these statements from the structured XBRL data NewGenIvf Group Limited files with the SEC. It is provided for information only and is not investment advice.